Welcome to the e-CCO Library!

P702: Off-label drug use in patients with inflammatory bowel disease: a national survey among tertiary care centres
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

M. Simsek*1, F. Hoentjen2, B. Oldenburg3, C. Y. Ponsioen4, J. van der Woude5, A. E. van der Meulen6, M. Pierik7, G. Dijkstra8, N. K. de Boer1

Created: Friday, 22 February 2019, 9:41 AM
P703 Addition of azathioprine to switch of anti-TNF in patients with IBD in clinical relapse with pharacokinetic failure: A post hoc analysis of a prospective randomised trial using drug-tolerant assay
Year: 2020
Source:

ECCO'20 Vienna

Authors:

S. Paul1, N. Williet2, S. Nancey3, P. Veyrard2, G. Boschetti3, A.E. Berger1, B. Flourie3, L. Peyrin Biroulet4, X. Roblin2

Created: Thursday, 30 January 2020, 10:12 AM
P703: Clinical, radiographic and endoscopic remission with vedolizumab treatment in Crohn’s disease
Year: 2018
Source: ECCO '18 Vienna
Authors:

P.G. Kotze*, C. Ma, A. Almutairdi, A. Al-Damarki, S. Devlin, G. Kaplan, C. Seow, K. Novak, C. Lu, J. Ferraz, M. Stewart, M. Buresi, M. Mathivanan, H. Jijon, J. Heatherington, M.-L. Martin, R. Panaccione

Created: Thursday, 21 February 2019, 9:14 AM
P703: Gut bacteria composition and familiality echo Inflammatory Bowel Disease type and pathological spectrum
Year: 2022
Source: ECCO'22
Authors: Martinez-Gili, L.(1);Gordon, H.(2);Blad, W.(2);McDonald, J.A.K.(1);Holmes, E.(1);Marchesi, J.R.(1);Harbord, M.(2);
Created: Friday, 11 February 2022, 3:56 PM
P703: Real world experience of the transition from the intravenous to subcutaneous formulation of vedolizumab in inflammatory bowel disease: A review of current data
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Agboton, C.(1)*;Kamble, P.(1);
Created: Friday, 14 July 2023, 11:12 AM
P703: Risk of disease progression in patients with Crohn's disease after 7 years of follow-up in a Danish population-based inception cohort
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Burisch J.*1, Vind I.2, Prosberg M.2, Dubinsky M.3, Siegel C.A.4, Bendtsen F.2, Vester-Andersen M.2,5

Created: Wednesday, 20 February 2019, 10:36 AM
P703: The real-world long-term effectiveness of vedolizumab in inflammatory bowel diseases: a single-centre observational study
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

F. S. Macaluso*1, A. Croce1, R. Orlando1, M. Ventimiglia1, C. Sapienza1, F. Gambino1, E. Orlando1, M. Grova1, G. Rizzuto1, S. Renna1, M. Cottone1, A. Orlando1

Created: Friday, 22 February 2019, 9:41 AM
P704 The biennial direct pharmaceutical costs per treatment with biologics for the inflammatory bowel disease in Greece: A comparative calculation study
Year: 2020
Source:

ECCO'20 Vienna

Authors:

C. Liatsos1, A. Papaefthymiou1, N. Kyriakos1, M. Giakoumis1, M. Tzouvala2, M. Doulberis3, C. Mavrogiannis4, J. Kountouras5

Created: Thursday, 30 January 2020, 10:12 AM
P704: Association between trough levels of vedolizumab and therapy outcome in a cohort of patients with inflammatory bowel disease
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

J. O'Connell1, P. McDonagh1, K. Hazel2, J. Fiona3, C. Dunne1,4, R. Farrell2, G. Harewood3, K. Hartery1,4, O. Kelly2, F. MacCarthy4,5, S. McKiernan1,4, F. Murray3, C. O'Morain6, O. Aoibhlinn3, D. Kevans1,4

Created: Friday, 22 February 2019, 9:41 AM
P704: Bifidobacterium longum species protect murine colitis through different activation repertoires of immune cells
Year: 2022
Source: ECCO'22
Authors: Kim, J.H.(1,2);I Seul, P.(1,2);Mijeong, S.(1,2);YooJin, S.(1,2);Kibeom, K.(1,2);Hyun Woo, M.(1,2);Tae Il, K.(1,2);Won Ho, K.(1,2);Seung Won, K.(1,2,3);Jae Hee, C.(1,2,3);
Created: Friday, 11 February 2022, 3:56 PM
P704: The effect of antiTNFα and anti-integrin agents on liver steatosis in inlamatory bowel disease patients with non-alcoholic fatty liver disease
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Mitrovic, M.(1)*;Marković, S.(1);Kalaba, A.(2);Zarić, D.(1);Kralj, Đ.(1);Milić, A.(2);Svorcan, P.(1);
Created: Friday, 14 July 2023, 11:12 AM
P704: The impact of travel distance on disease outcomes in inflammatory bowel disease
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Borren N.*1,2, Tan W.1, Andrews E.1, Khalili H.1,3, Garber J.1,3, Yajnik V.1,3, Ananthakrishnan A.1,3

Created: Wednesday, 20 February 2019, 10:36 AM
P704: Ustekinumab induces limited mucosal healing after 6 months in a real-life, prospective cohort of patients with refractory Crohn’s disease
Year: 2018
Source: ECCO '18 Vienna
Authors:

B. Verstockt1,2*, M. Noman1, I. Aerden1, M. Peeters3, E. Brouwers3, V. Ballet1, L. Vandersmissen1,3, G. Van Assche1,2, A. Gils3, S. Vermeire1,2, M. Ferrante1,2

Created: Thursday, 21 February 2019, 9:14 AM
P705 Dietary practices and beliefs of patients with older-onset inflammatory bowel disease: A prospective UK study
Year: 2020
Source:

ECCO'20 Vienna

Authors:

B. Crooks1, J. McLaughlin2, J.K. Limdi1

Created: Thursday, 30 January 2020, 10:12 AM
P705: Incidence and risk factors of micronutrient deficiency in the patients with inflammatory bowel disease in Korea: folate, vitamin B12, 25-OH-vitamin D, ferritin
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

Y. E. Park*1, S. J. Park2, Y. Park2, J. H. Cheon2, T. I. Kim2, W. H. Kim2

Created: Friday, 22 February 2019, 9:41 AM
P705: Peripheral arterial disease is associated with an increased risk of elderly-onset inflammatory bowel disease
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Peerani F.*1, Chang H.2, Ungaro R.3, Torres J.3, Atreja A.3, Colombel J.-F.3

Created: Wednesday, 20 February 2019, 10:36 AM
P705: Switching from intravenous to subcutaneous infliximab: clinical and patient experience outcomes
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Nowell, E.(1);Laird, S.(1);Bailey, E.(1);Brownson, E.(1)*;Saunders, J.(1);Seenan, J.P.(1);Smith, G.(1);Macdonald, J.(1);
Created: Friday, 14 July 2023, 11:12 AM
P705: Switching from originator to biosimilar infliximab—real-world data from 18 months prospective follow-up of a single-centre IBD population
Year: 2018
Source: ECCO '18 Vienna
Authors:

M.L. Hoivik1*, L.C. Buer1,2, N. Bolstad3, B. Moum1,2, A.W. Medhus1

Created: Thursday, 21 February 2019, 9:14 AM
P705: The effects of commonly consumed dietary fibres on the gut microbiome and its fibre fermentative capacity in adults with inflammatory bowel disease in remission
Year: 2022
Source: ECCO'22
Authors: Gerasimidis, K.(1);Nichols, B.(1);McGowan, M.(1);Svolos, V.(1);Papadopoulou, R.(1);Kokkorou, M.(1);Rebull, M.(1);Bello Gonzalez, T.(1);Hansen, R.(1);Russell, R.K.(1);Gaya, D.R.(1);
Created: Friday, 11 February 2022, 3:56 PM
P706 Adalimumab drug levels at secondary loss of response in Crohn’s disease; are we aiming high enough? A retrospective, international multi-centre study
Year: 2020
Source:

ECCO'20 Vienna

Authors:

A. Swaine1, R. Reynolds2, X. Roblin3, D. Gibson1, C. Martin4, P. Irving2, M. Sparrow1, M. Ward1

Created: Thursday, 30 January 2020, 10:12 AM